Flash FinanceUS
Market closed · weekend S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026

Johnson & Johnson (JNJ)

NYSE Health Care Pharmaceuticals S&P 500Dow 30
$276.22
+3.90 (+1.43%)
Close of Nov 06, 2026 · end-of-day data
Source: Johnson & Johnson's 10-K / 10-Q XBRL data on SEC EDGAR · fetched Nov 05, 2026

Revenue, net income & free cash flow

Income statement

fiscal years · USD
Fiscal yearFY2017FY2017FY2018FY2019FY2021FY2022FY2023FY2023FY2024FY2025
Revenue$71.89B$76.45B$81.58B$82.06B$82.58B$78.74B$79.99B$85.16B$88.82B$94.19B
Cost of revenue$21.79B$25.44B$27.09B$27.56B$28.43B$23.40B$24.60B$26.55B$27.47B$30.26B
Gross profit$50.10B$51.01B$54.49B$54.50B$54.16B$55.34B$55.39B$58.61B$61.35B$63.94B
Research & development$9.14B$10.59B$10.78B$11.36B$12.16B$0$0$483.00M$1.84B$109.00M
Selling, general & admin$20.07B$21.52B$22.54B$22.18B$22.08B$20.12B$20.25B$21.51B$22.87B$23.68B
Interest expense$726.00M$934.00M$1.00B$318.00M$201.00M$183.00M$276.00M$772.00M$755.00M$971.00M
Pre-tax income$19.80B$17.67B$18.00B$17.33B$16.50B$19.18B$19.36B$15.06B$16.69B$32.58B
Income tax$3.26B$16.37B$2.70B$2.21B$1.78B$1.38B$2.99B$1.74B$2.62B$5.78B
Net income$16.54B$1.30B$15.30B$15.12B$14.71B$20.88B$17.94B$35.15B$14.07B$26.80B
EPS (basic)$6.04$0.48$5.70$5.72$5.59$7.93$6.83$13.88$5.84$11.13
EPS (diluted)$5.93$0.47$5.61$5.63$5.51$7.81$6.73$13.72$5.79$11.03
Diluted shares2.79B2.75B2.73B2.68B2.67B2.67B2.66B2.56B2.43B2.43B
Gross margin69.7%66.7%66.8%66.4%65.6%70.3%69.3%68.8%69.1%67.9%
Net margin23.0%1.7%18.8%18.4%17.8%26.5%22.4%41.3%15.8%28.5%

Balance sheet

fiscal years · USD
Fiscal yearFY2017FY2017FY2018FY2019FY2021FY2022FY2023FY2023FY2024FY2025
Cash & equivalents$18.97B$17.82B$18.11B$17.30B$13.98B$14.49B$12.89B$21.86B$24.11B$19.71B
Short-term investments$22.93B$472.00M$1.58B$1.98B$11.20B$17.12B$9.39B$1.07B$417.00M$393.00M
Receivables$11.70B$13.49B$14.10B$14.48B$13.58B$15.28B$14.04B$14.87B$14.84B$17.18B
Inventory$8.14B$8.77B$8.60B$9.02B$9.34B$10.39B$10.27B$11.18B$12.44B$14.19B
Total current assets$65.03B$43.09B$46.03B$45.27B$51.24B$60.98B$55.29B$53.49B$55.89B$55.62B
Goodwill$22.80B$31.91B$30.45B$33.64B$36.39B$25.44B$36.05B$36.56B$44.20B$48.77B
Total assets$141.21B$157.30B$152.95B$157.73B$174.89B$182.02B$187.38B$167.56B$180.10B$199.21B
Total current liabilities$26.29B$30.54B$31.23B$35.96B$42.49B$45.23B$55.80B$46.28B$50.32B$54.13B
Short-term debt$4.70B$3.90B$2.80B$1.20B$2.60B$3.80B$12.80B$3.50B$6.00B$8.50B
Long-term debt$22.44B$30.68B$27.68B$26.49B$32.63B$29.98B$26.89B$25.88B$30.65B$39.44B
Total debt$27.14B$34.58B$30.48B$27.69B$35.23B$33.78B$39.69B$29.38B$36.65B$47.94B
Total liabilities$70.79B$97.14B$93.20B$98.26B$111.62B$108.00B$110.57B$98.78B$108.61B$117.67B
Shareholders' equity$70.42B$60.16B$59.75B$59.47B$63.28B$74.02B$76.80B$68.77B$71.49B$81.54B

Cash flow

fiscal years · USD
Fiscal yearFY2017FY2017FY2018FY2019FY2021FY2022FY2023FY2023FY2024FY2025
Operating cash flow$18.77B$21.06B$22.20B$23.42B$23.54B$23.41B$21.19B$22.79B$24.27B$24.53B
Capital expenditures$3.23B$3.28B$3.67B$3.50B$3.35B$3.65B$4.01B$4.54B$4.42B$4.83B
Free cash flow$15.54B$17.78B$18.53B$19.92B$20.19B$19.76B$17.18B$18.25B$19.84B$19.70B
Investing cash flow-$4.76B-$14.87B-$3.17B-$6.19B-$20.82B-$8.68B-$12.37B$878.00M-$18.60B-$23.59B
Financing cash flow-$8.55B-$7.67B-$18.51B-$18.02B-$6.12B-$14.05B-$8.87B-$15.82B-$3.13B-$5.54B
Share buybacks$8.98B$6.36B$5.87B$6.75B$3.22B$3.46B$6.04B$5.05B$2.43B$5.95B
Stock-based compensation$878.00M$962.00M$978.00M$977.00M$1.00B$1.14B$1.14B$1.16B$1.18B$1.35B
Depreciation & amortization$3.75B$5.64B$6.93B$7.01B$7.23B$7.39B$6.97B$7.49B$7.34B$7.50B

Quarterly figures are rebuilt from the year-to-date totals companies report — Q4 is the full year minus the first nine months, since no 10-Q is filed for it. Values are as filed; later restatements replace earlier ones. Fiscal years are labelled by the calendar year in which they end.